New hope for Tough-to-Treat head and neck cancers
NCT ID NCT03360890
Summary
This study is testing whether combining an immunotherapy drug (pembrolizumab) with a chemotherapy drug (docetaxel) can help control advanced thyroid and salivary gland cancers that have not responded well to standard treatments. It is for adults with these specific cancers who have run out of other good treatment options. The main goal is to see if the combination can shrink tumors and control the disease for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.